Dabrafenib

CAS: 1195765-45-7

Ref. TR-D101000

Informação sobre produto

• Nome: Dabrafenib
• Sinónimos: N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-benzenesulfonamide, Dabarefenib, GSK 2118436, Tafinlar, GSK 2118436A, Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, Debrafenib free base, Gsk 2118436, Gsk 436, N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide, N-[3-[5-(2-Aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide, Tafmlar

Descrição

Applications Dabrafenib is an inhibitor of mutated BRAF kinase and has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.
References Hauschild, A., et al.: Lancet, 380, 358 (2012); Falchook, G.S., et al.: Lancet, 379, 1893 (2012); Ascierto, P.A., et al.: J. Clin. Oncol., 31, 3205 (2013);

• Marca: TRC

Propriedades químicas

• Peso molecular: 519.56
• Fórmula: C₂₃H₂₀F₃N₅O₂S₂
• Cor/forma: Neat
• InChI: InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)
• Chave InChI: InChIKey=BFSMGDJOXZAERB-UHFFFAOYSA-N
• SMILES: CC(C)(C)c1nc(-c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(-c2ccnc(N)n2)s1